Ionis Pharmaceuticals, Inc. (IONS)
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
Shares of Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) are down 9% intraday, changing hands near $58.30 after opening the session at $64.27.
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Ionis grants Recordati ex-U.S. rights to zilganersen for Alexander disease while retaining U.S. commercialization and securing upfront and royalty payments.
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript
Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
Ionis Pharmaceuticals remains a Buy, with a compelling bull case despite a >125% 12-month share price increase. IONS is transitioning from niche indications to multi-billion-dollar markets, leveraging key partnerships and upcoming product launches. Projected 2030 revenues exceed $5bn, driven by Tryngolza, Dawnzera, and significant royalty streams from eplontersen, bepiroversen, and pelacarsen.
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Ionis Pharmaceuticals NASDAQ: IONS highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets' Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launches into a broader commercial and late-stage development phase.
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals NASDAQ: IONS products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocrine Biosciences' commercial and pipeline strategy. Get Ionis Pharmaceuticals alerts:Sign UpIonis Highlights TRYNGOLZA Opportunity in Severe Hypertriglyceridemia Todd Tushla, vice president of investor relations, said Ionis is preparing for a potential June 30 FDA action date for olezarsen in severe hypertriglyceridemia, or sHTG.
